Increased PYCR1 mRNA predicts poor prognosis in kidney adenocarcinoma: A study based on TCGA database.
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Carcinoma, Renal Cell
/ genetics
China
Databases, Factual
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Kidney Neoplasms
/ genetics
Male
Middle Aged
Prognosis
Pyrroline Carboxylate Reductases
/ metabolism
RNA, Messenger
/ metabolism
Young Adult
delta-1-Pyrroline-5-Carboxylate Reductase
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Sep 2021
24 Sep 2021
Historique:
received:
11
03
2021
accepted:
18
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
2
10
2021
Statut:
ppublish
Résumé
The pyrroline-5-carboxylate reductase 1 (PYCR1) plays important roles in cancers, but its contribution to adenocarcinoma of the kidney (AK) and the potential mechanism remain to be clarified. In this study, we aimed to demonstrate the relationship between PYCR1 mRNA and AK based on The Cancer Genome Atlas database.PYCR1 mRNA in AK and normal tissues was compared using Wilcoxon rank sum test. The relationship between PYCR1 mRNA and clinicopathological characters was evaluated using logistic regression. The association between PYCR1 mRNA and survival rate was evaluated using Kaplan-Meier test and Cox regression of univariate and multivariate analysis. Additionally, Gene Set Enrichment Analysis was conducted to annotate the biological function of PYCR1 mRNA.Increased PYCR1 mRNA was found in AK tissues. Increased PYCR1 mRNA was related to high histologic grade, clinical stage, and lymph node and distant metastasis. Kaplan-Meier survival analysis and univariate analysis showed that AK patients with increased PYCR1 mRNA had worse prognosis than those without. PYCR1 mRNA remained independently associated with overall survival (HR: 1.34; 95% CI: 1.07-1.66; P = .009) in multivariate analysis. The Gene Set Enrichment Analysis suggested that ribosome, proteasome, inhibition of p53 signaling pathway, extracellular matrix receptor interaction, and homologous recombination were differentially enriched in increased PYCR1 mRNA phenotype.Increased PYCR1 mRNA is a potential marker in patients with AK. More importantly, p53 pathway, ribosome, proteasome, extracellular matrix receptor interaction, and homologous are differentially enriched in AK patients with increased PYCR1 mRNA.
Identifiants
pubmed: 34559102
doi: 10.1097/MD.0000000000027145
pii: 00005792-202109240-00011
pmc: PMC8462611
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Messenger
0
Pyrroline Carboxylate Reductases
EC 1.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27145Subventions
Organisme : Postdoctoral Science Foundation
ID : 2017M612870
Organisme : Natural Science Foundation of Liaoning Province
ID : 2019-ZD-0807
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:07–30.
Solarek W, Koper M, Lewicki S, Szczylik C, Czarnecka AM. Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. J Cell Commun Signal 2019;13:381–94.
Zhang H, Wang Z, Xie L, et al. Molecular recognition and in-vitro-targeted inhibition of renal cell carcinoma using a DNA aptamer. Mol Ther Nucleic Acids 2018;12:758–68.
Wu H, Zhang J. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: a study based on TCGA data. Gynecol Oncol 2018;149:592–7.
Verbruggen N, Hermans C. Proline accumulation in plants: a review. Amino Acids 2008;35:753–9.
Christensen EM, Patel SM, Korasick DA, et al. Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1. J Biol Chem 2017;292:7233–43.
Phang JM, Liu W. Proline metabolism and cancer. Front Biosci (Landmark Ed) 2012;17:1835–45.
Phang JM, Liu W, Hancock CN, Fischer JW. Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 2015;18:71–7.
Phang JM. Proline metabolism in cell regulation and cancer biology: recent advances and hypotheses. Antioxid Redox Signal 2019;30:635–49.
Christgen SL, Becker DF. Role of proline in pathogen and host interactions. Antioxid Redox Signal 2019;30:683–709.
Elia I, Broekaert D, Christen S, et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun 2017;8:15267.
Kuo ML, Lee MB, Tang M, et al. PYCR1 and PYCR2 interact and collaborate with RRM2B to protect cells from overt oxidative stress. Sci Rep 2016;6:18846.
Ding J, Kuo ML, Su L, et al. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis 2017;38:519–31.
Zeng T, Zhu L, Liao M, et al. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med Oncol 2017;34:27.
Cai F, Miao Y, Liu C, et al. Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Oncol Lett 2018;15:731–40.
Craze ML, Cheung H, Jewa N, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer 2018;118:258–65.
Olivares O, Mayers JR, Gouirand V, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun 2017;8:16031.
Hollinshead KER, Munford H, Eales KL, et al. Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis. Cell Rep 2018;22:3107–14.
Togashi Y, Arao T, Kato H, et al. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget 2014;5:2962–73.
Nilsson R, Jain M, Madhusudhan N, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun 2014;5:3128.
Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169–80.
Zhang Y, Li Q, Wei S, et al. ZNF143 suppresses cell apoptosis and promotes proliferation in gastric cancer via ROS/p53 axis. Dis Markers 2020;2020:5863178.
Lu ZW, Wen D, Wei WJ, et al. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma. Oncol Rep 2020;43:783–94.
Cen B, Lang JD, Du Y, et al. Prostaglandin E(2) induces miR675-5p to promote colorectal tumor metastasis via modulation of p53 expression. Gastroenterology 2020;158:971–84.e10.
Guo L, Cui C, Zhang K, et al. Kindlin-2 links mechano-environment to proline synthesis and tumor growth. Nat Commun 2019;10:845.
Wang T, Zhang WS, Wang ZX, et al. RAPTOR promotes colorectal cancer proliferation by inducing mTORC1 and upregulating ribosome assembly factor URB1. Cancer Med 2020;9:1529–43.
Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat 2020;48:100663.
Wang M, Yang J, Wang C. Shen Shuai II recipe attenuates apoptosis in 5/6 renal ablation/infarction rats by inhibiting p53 and the mitochondrial pathway of apoptosis. Oxid Med Cell Longev 2020;2020:7083575.
Shenoy N, Kessel R, Bhagat TD, et al. Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol 2012;5:32.